

Freedom of Information Request

Q1. In the past 6 months, how many patients has your trust treated [for any condition] with the following drugs:

- Aripiprazole long-acting injectable (Abilify Maintena)
- Olanzapine pamoate (Zypadhera) – one patient
- Paliperidone palmitate, once monthly (Xeplion)
- Paliperidone palmitate, three monthly (Trevicta)
- Risperidone long-acting injectable (Risperdal Consta)
- Flupentixol decanoate (Depixol)
- Fluphenazine decanoate (Modecate)
- Haloperidol decanoate (Haldol Decanoate)
- Pipotiazine palmitate (Piportil)
- Zuclopenthixol decanoate (Clopixol)

Q2. Within your organisation how many patients are currently [within the past 6 months] being treated for Schizophrenia (ICD code: F20)

Q3. Of the Schizophrenia patients ONLY, how many are currently [within the past 6 months] being treated with the following drugs:

- Aripiprazole long-acting injectable (Abilify Maintena)
- Olanzapine pamoate (Zypadhera) – one patient
- Paliperidone palmitate, once monthly (Xeplion)
- Paliperidone palmitate, three monthly (Trevicta)
- Risperidone long-acting injectable (Risperdal Consta)
- Flupentixol decanoate (Depixol)
- Fluphenazine decanoate (Modecate)
- Haloperidol decanoate (Haldol Decanoate)
- Pipotiazine palmitate (Piportil)
- Zuclopenthixol decanoate (Clopixol)

NHSCT Pharmacy are unable to provide a response to Q1 and Q3 with the exception of olanzapine pamoate (Zypadhera).

The reason NHSCT pharmacy are unable to identify the number of patients treated is because the medicines listed are available for use at ward level. They are not always charged on an individual patient basis.